STRATA Skin Sciences (NASDAQ:SSKN) Given a $5.00 Price Target at HC Wainwright

HC Wainwright set a $5.00 price target on STRATA Skin Sciences (NASDAQ:SSKN) in a report released on Monday morning, Stock Target Advisor reports. The brokerage currently has a buy rating on the medical device company’s stock.

A number of other research firms have also commented on SSKN. ValuEngine lowered shares of Zumiez from a hold rating to a sell rating in a research note on Tuesday, July 2nd. Northland Securities set a $5.00 price objective on shares of Communications Systems and gave the company a buy rating in a research note on Tuesday, May 14th. Finally, Zacks Investment Research raised shares of York Water from a sell rating to a hold rating in a research note on Saturday, June 1st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $4.92.

SSKN stock opened at $2.45 on Monday. STRATA Skin Sciences has a one year low of $1.76 and a one year high of $3.88. The firm’s 50-day moving average price is $2.28.



Several hedge funds and other institutional investors have recently bought and sold shares of SSKN. Northern Trust Corp purchased a new stake in shares of STRATA Skin Sciences in the fourth quarter worth approximately $36,000. Virtu Financial LLC purchased a new stake in shares of STRATA Skin Sciences in the first quarter worth approximately $39,000. Acadian Asset Management LLC lifted its position in shares of STRATA Skin Sciences by 79.3% in the fourth quarter. Acadian Asset Management LLC now owns 32,568 shares of the medical device company’s stock worth $85,000 after purchasing an additional 14,408 shares in the last quarter. Meitav Dash Investments Ltd. lifted its position in shares of STRATA Skin Sciences by 12.8% in the first quarter. Meitav Dash Investments Ltd. now owns 807,234 shares of the medical device company’s stock worth $2,314,000 after purchasing an additional 91,418 shares in the last quarter. Finally, Nantahala Capital Management LLC lifted its position in shares of STRATA Skin Sciences by 8.2% in the fourth quarter. Nantahala Capital Management LLC now owns 2,768,001 shares of the medical device company’s stock worth $7,197,000 after purchasing an additional 209,110 shares in the last quarter. 30.96% of the stock is owned by institutional investors and hedge funds.

STRATA Skin Sciences Company Profile

STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.

Further Reading: Overbought

Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.